Protara Therapeutics, INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Several entities associated with Millennium Management have reported a combined beneficial ownership of over 5% in Protara Therapeutics, Inc.

Janus Henderson Group plc has reported beneficial ownership of 5,207,011 shares, representing 9.6% of Protara Therapeutics, Inc.'s common stock, as of March 31, 2026.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 5.1% beneficial ownership stake in Protara Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.7% of Protara Therapeutics, Inc.'s common stock as of December 31, 2025.

Janus Henderson Group plc and its affiliate funds have reported an 11.0% beneficial ownership in Protara Therapeutics, Inc. common stock.

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Protara Therapeutics, Inc. as of June 30, 2025.

Janus Henderson Group PLC and its affiliates have reported a 10.6% beneficial ownership stake in Protara Therapeutics, Inc. common stock as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, revealing a 5.6% beneficial ownership stake in Protara Therapeutics, Inc. as of June 30, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have reported a combined beneficial ownership of 10.5% in Protara Therapeutics, Inc. as of March 31, 2025.

Adage Capital Management, L.P., along with its principals Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G indicating they no longer hold a reportable beneficial ownership stake in Protara Therapeutics, Inc.

Opaleye Management, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.71% in Protara Therapeutics, Inc., indicating a reduction below the 5% threshold.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 10.3% in Protara Therapeutics, Inc.'s common stock, held for investment purposes.

RA Capital Management, along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., have filed an amended Schedule 13G/A disclosing a passive beneficial ownership of 9.9% in Protara Therapeutics, Inc. as of December 31, 2024.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a passive beneficial ownership stake of up to 4.7% in Protara Therapeutics, Inc. as of December 31, 2024.

Woodline Partners LP, an investment adviser, has disclosed a 3.9% passive beneficial ownership stake in Protara Therapeutics, Inc., including shares underlying warrants, as of December 31, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed passive beneficial ownership stakes of 6.6% and 6.0% respectively, in Protara Therapeutics, Inc. common stock as of December 31, 2024.

Opaleye Management, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.32% of Protara Therapeutics, Inc.'s common stock as of December 31, 2024.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a passive beneficial ownership of 6.56% in Protara Therapeutics, Inc.'s common stock.